GlobeNewsWire
22 Nov 2026, 21:20 UTC · 1h ago
Invivyd to Host Conference Call to Announce Results from Interim Analysis of Phase 3 DECLARATION Clinical Trial on November 23, 2026
Impact · against what's priced in
Invivyd is set to release interim Phase 3 DECLARATION trial data, creating a binary catalyst for the stock. While the announcement of the call is administrative, the upcoming data represents a significant volatility event that can fundamentally re-rate the company's valuation.
Scored by the NIS engine · methodology.





